Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no 2.7mg dose of Wegovy. The licensed weekly doses of semaglutide for weight management in the UK are 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg, titrated by a prescriber across roughly four-week steps. If you have seen a listing for Wegovy 2.7mg, it does not reflect a licensed UK product. Private Wegovy pricing in the UK varies by provider and by dose, and any legitimate price must include clinical assessment and a valid prescription. These are prescription-only medicines; a qualified prescriber decides whether semaglutide is appropriate for you, and no reputable pharmacy can supply it otherwise. At nume, everything involved in your treatment, from consultation through to next-working-day delivery, is wrapped into one transparent price with no hidden fees and no subscription.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The 2.7mg figure almost certainly originates from the US market, where Ozempic (semaglutide for type 2 diabetes) is available at a 2mg weekly dose, or from confusion with Wegovy's 2.4mg maintenance dose being misquoted online. In the UK, Wegovy's licensed titration schedule runs: 0.25mg, then 0.5mg, 1mg, 1.7mg, and 2.4mg, that is the full list. A 7.2mg maintenance dose was approved by the MHRA in April 2026, supplied via a dedicated pre-filled single-dose pen. There is no 2.7mg pen in any of those steps. If an online seller lists a Wegovy 2.7mg product, treat that as a significant red flag. The MHRA has warned explicitly about fake weight-loss pens circulating through unverified online channels, some of which have contained insulin rather than semaglutide. Check any pharmacy you are considering on the GPhC register before handing over payment or personal information.
For legitimate UK private treatment, prices are quoted per pen, and the pen covers four weekly doses. Eli Lilly's September 2025 price increase shifted the market significantly for tirzepatide, but Novo Nordisk's Wegovy has its own pricing structure. Across providers, typical private monthly costs reported since mid-2025 range roughly from £149 to £375 depending on the dose and the provider, the higher doses sit toward the upper end of that range. Those figures are widely reported market observations, not a promise of what you will pay. The full overview of Wegovy pricing in the UK goes into more detail across all doses, and you can compare costs at specific points in the titration on pages like the 1.7mg price page or the 2.4mg page. If you are starting out and want to understand what the opening dose costs before committing to the full titration, you can find a breakdown on the page covering the 2.5mg starting dose price. What matters as much as the headline figure is what that figure actually buys.
Some providers price the medicine pen alone. Consultation fees, prescription charges, delivery, and clinical aftercare are then added separately. By the time those are totalled, the apparently lower starting price may not hold. Payday orders, holiday-week rushes, or a dose change mid-month can all expose gaps in a service that charges per interaction. At nume, a single transparent price covers the consultation, the prescriber's review, the prescription, the medicine, free next-working-day DPD delivery, and access to clinical aftercare seven days a week. There are no repeat subscription charges and no auto-renewals; every repeat order is reviewed again by a prescriber before it ships. We are not trying to win on price. A clinician-led service with genuine safety infrastructure costs what it costs, and we think the right question is not which provider charges the least, but which one you would trust to get this right. You can read more about how our prescribers work on our clinical team page.
A small saving on a GLP-1 medicine from an unverified seller is not a saving in any meaningful sense. The MHRA's enforcement work through 2025 included the seizure of roughly 20 million doses of illegally traded weight-loss medicines (around £45m in street value) and the raid of a UK site manufacturing counterfeit tirzepatide pens. Similar risks apply across the GLP-1 category. Semaglutide is a prescription-only medicine; under UK law, supplying it without a valid prescription following clinical assessment is illegal, and a product supplied that way carries no guarantee of authenticity. For guidance on what NHS access looks like and whether you might qualify, the NHS Wegovy page lays that out clearly. If you have questions about whether semaglutide is right for your situation, the faqs page covers the most common ones, and you can always reach the team via contact. The sensible next step is a conversation with a prescriber, not a price comparison. Speak to our prescribers through a free consultation and find out whether Wegovy is clinically suitable for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.